TY  - JOUR 
AU  - Pérez Encinas, Manuel Mateo
PY  - 2015
SN  - 2045-7634
UR  - http://hdl.handle.net/20.500.11940/2944
LA  - eng
TI  - Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months
DO  - 10.1002/cam4.440
M2  - 995
VL  - 4
ER  -